Abstracts, Posters, and Letters to the Editor
  1. M. El Shahawy, et. al.; “Arrhythmias and the Varieties of Sleep” N.E.J.M. 282:815, April 2, 1970. (Letter to the Editor)
  2. M. El Shahawy, et. al.; “Magnesium Deficiency and the Hyperthyroid Heart” Summaries of Communications of First International Symposium on Magnesium Deficiency in Human Pathology, page 79, May 1971.
  3. M. El Shahawy, et. al.; Hypertension and Potassium” J.A.M.A. 217:7, August 16, 1971, 969.  (Letter to the Editor)
  4. M. El Shahawy, et. al.; “Cardiovascular Effects of Magnesium Deficiency and Thyroxine Administration” Chest, Vol.60, September 1971, page 306. (Cecile Lehman Mayer Research)
  5. M. El Shahawy, et. al.; “Increased Plasma Renin Activity and Secondary Aldosteronism in Hypothyroidism: Augmentation By Magnesium Deficiency” Circ. Res. Suppl. October 1971, page 129.
  6. M. El Shahawy, et. al.; “Role of Magnesium in Myocardial Function” N.E.J.M. 286:217. (Letter to the Editor) 1972.
  7. M. El Shahawy, et. al.; “Magnesium Deficiency Cardiomyopathy in Hyperthyroid Dogs” Clin. Res. Vol. XX, No.3, April 1972, page 39.
  8. M. El Shahawy, et. al.; “Thyroxin, Magnesium, and Lipids” Clin. Res. Vol. XX, No. 3, April 1972, page 397.
  9. M. El Shahawy, et. al.; “Effective Renin Activity in Plasma of Children with Kwashiorkor” Lancet, Vol1:1241, 1972.
  10. M. El Shahawy, et. al.; “The Effect of Thyroid Hormone on Intracardiac Conduction with and without Propranolol” Circulation Research Supplement, October 1972, page 40.
  11. Albert A. Carr, M. El Shahawy, et. al.; “The Effect of Thyroid Hormone and B-Blockade on Renin Release in Hyperthyroid Dogs” Circulation Research Supplement, October 1972, page 71.
  12. M. El Shahawy, et. al.; “The Effect of Hyperkalemia on Intracardiac Conduction in Hyperthyroid Dogs” Clin. Res., January 1973, page 36.
  13. M. El Shahawy, et. al.; “The Effect of Thyroid Hormone on Intracardiac Conduction in Acute and Chronic Studies” Clin. Res. Vol. XXI, No. 3, April 1973, page 416.
  14. M. El Shahawy, et. al.; “Fine Structural Changes in Cardiac Muscle of Hyperthyroid Dogs” Clin. Res. Vol. XXI, No. 3, April 1973.
  15. M. Stefadouros, M. El Shahawy, et.al.; “Non-Invasive Study of the Effect of Isometric Exercise on the Size and Performance of the Normal Heart” Circulation Supplement, October 1973, XLVIII, No. 4, page 48.
  16. M. El Shahawy, et. al.; “Effect of Tilt on Left Ventricular Function in Man” Circulation Supplement, October 1973, XLVIII, No. 4, October 1973, page 160.
  17. M. E1 Shahawy, et. al.; “L’ Effet De L’ Administration Acute De L’ Hormone Thyroidizue sur la Transmission Intra-Cardiac” World Congress of Cardiology, September 1974, Abstract #569.
  18. M. E1 Shahawy, et. al.; “Magnesium Deficiency and the Thyrotoxic Heart” World Congress of Cardiology Communications, Abstract #568.
  19. M. El Shahawy, et. al.; “Effect of Acute Thyroid Hormone” Administration on Intracardiac Conduction. Supplement III, Circulation 49 & 50, October 1974, page 171.
  20. M. El Shahawy, et. al., C.R. Conti; “Thyroid Hormone and the Prevention of Heart Block” Journal of Clinical Research, VXXIII, No. 5, BA.
  21. M. El Shahawy, M.D., M.S., F.E.S.C., F.A.C.C., et al.: “Darusentan Antihypertensive Effect in Patients with Resistant Hypertension”, Presented at the 55th Annual Scientific Session American College of Cardiology, March 12, 2006, Atlanta, GA
  22. M. El Shahawy, M.D. et al.: “Early Cardiovascular Disease Risk Score as a More Sensitive Guide Than Framingham Score for Cardiovascular Risk Prediction in Males and It’s Correlation With Hypertension”, Presented at the 24th Annual American Society of Hypertension., May 6-9, 2009. San Francisco, CA.
  23. M. El Shahawy, M.D. et al.: “Time to Mandate a More Accurate Tool to Assess CVD risk in Women Beyond Framingham”, presented at the International Conference on Early Disease Detection and Prevention (EDDP), Munich, Germany, February 2010.
  24. M. El Shahawy, M.D. et al.: “Why Early Screening For CVD Risk Stratification With A More Accurate Risk Score Method Must Be Mandated By Those Who Care About Our Health?”, presented at the International Conference on Early Disease Detection and Prevention (EDDP), Munich, Germany, February 2010.
  25. M. El Shahawy, M.D. et al.: “Rise in Systolic Blood Pressure (SBP) Over 30 mmHg After Mild Exercise as a New Marker for Early Cardiovascular Disease Risk Stratification in Asymptomatic Normotensive Patients Regardless of Sex”, presented at the International Conference on Early Disease Detection and Prevention (EDDP), Munich, Germany, February 2010.
  26. M. El Shahawy, M.D. et al.: “Carotid Intima Medial Thickness (CIMT) Measurement For Cardiovascular Disease (CVD) Risk Stratification In Newly Diagnosed Asymptomatic Hypertensive Patients”, Presented at the 25th Annual American Society of Hypertension., May 1-4, 2010, New York, NY.
  27. M. El Shahawy, M.D. et al.: “Carotid Intima Medial Thickness (CIMT) and small artery elasticity (C2) as a powerful tool for Cardiovascular Disease (CVD) risk stratification as compared with high-sensitivityC-reactive protein (hCRP) regardless of sex”, Presented at the International Academy Of Cardiology 15th World Congress on Heart Disease Annual Scientific Sessions 2010, Vancouver, B.C., Canada, July 24-27, 2010.
  28. M. El Shahawy, M.D. et al.: “Novel Approaches for Risk Stratification and Managment of Asymptomatic Metabolic Syndrome Subjects: Is Metabolic Syndrome a Marker of Coronary Artery Disease in All?”, Presented at the Society for Cardiovascular Computed Tomography [SCCT'] Fifth Annual Scientific Meeting July 15-18, 2010.
  29. M. El Shahawy, M.D. et al.: “Value of Pro BNP as a Screening Tool for the Assessment of Early Cardiovascular Disease Risk Assessment”, presented at the American College of Physicians Florida Chapter Associate Meeting - March 11-13th, 2011, Orlando, FL.
  30. M. El Shahawy, M.D. et al.:  “Abnormal  Systolic Blood Pressure Rise Post Exercise as a Marker for Early Cardiovascular   Disease Risk assessment in Asymptomatic Normotensive Subjects”, presented at the American College of Physicians, Florida Chapter Associate Meeting - March 11-13th, 2011, Orlando, FL.
  31. M. El Shahawy, M.D. et al.: “Is metabolic syndrome cardiovascular disease (CVD) risk equivalent?”,  presented at the European Society of Cardiology (ESC) EuroPRevent  2011 Annual Meeting, Geneva, Switzerland, April 2011.
  32. M. El Shahawy, M.D. et al.: “Predictors of early cardiovascular disease risk in asymptomatic Metabolic Syndrome    individuals: Which test is best?”, presented at the AHA Quality Care and Outcomes Research in Cardiovascular Disease and Stroke 2011 Scientific Sessions, Washington, DC, May 2011.
  33. M. El Shahawy, M.D. et al.: “Pre-Hypertension: is it a disease?”, presented at the American Society of Hypertension 2011 Annual Scientific  Meeting, New York, NY, May 2011;
  34. M. El Shahawy, M.D. et al.: “Novel method for assessing the prevalence of Hypertension and Cardiovascular disease Risk in a Community Screening Program in a South East Region of US”, presented at the American Society of Hypertension 2001 Annual Scientific Meeting, New York, NY, May 2011.
  35. M. El Shahawy, M.D. et al.: “Is Epicardial Fat Volume gender Specific?  Is its excess a villain for Cardiovascular Disease Risk in Metabolic Syndrome subjects”, presented At the Sixth Annual Scientific Meeting of the Society for Cardiovascular Computed Tomography (SCCT), Denver, Colorado, July 2011;
  36. M. El Shahawy, M.D. et al.: “Obesity and cardiovascular disease (CVD): an association or a cause and effect relationship?”, presented at the European Society of Cardiology 2011 Annual Scientific Meeting, Paris, France, August 2011.
  37. M. El Shahawy, M.D. et al.:  “The Value of Optimal Blood Pressure Control in Reducing Functional and Structural Cardiovascular Abnormalities”, presented at 15th Annual Scientific Meeting of the Heart Failure Society of America, September 18-21, Boston, MA.
  38. M. El Shahawy, M.D. et al.: “Obesity Even Without Comorbidity Is A Risk Marker For Stroke” presented at the American Heart Association/American Stroke Association's International Stroke Conference, Feb. 1-3 in New Orleans, LA
  39. M. El Shahawy, M.D. et al.: “Obesity Even Without Co-morbidity Harbors more Cardiovascular Structural and Functional Abnormalities than what you think! Time for Early CV Screening!” presented at the Quality of Care and Outcomes Research 2012 Scientific Sessions in Atlanta, GA, May 9-11, 2012.
  40. M. El Shahawy, M.D. et al.: “What are the early cardiovascular (CV) structural and functional abnormalities associated with obesity?”, presented at the ESC Heart Failure 2012 Congress - held in Belgrade Serbia, 19-22 May 2012.
  41. M. El Shahawy, M.D. et al.: “Abnormal Blood Pressure (BP) Rise Post Mild Exercise In Hypertensive Patients Is An Additive Risk Factor”, presented at the American Society of Hypertension 2012 Annual Scientific Meeting, New York, NY, May 19th, 2012.
  42. M. El Shahawy, M.D. et al.: “Cardiovascular Disease Is The Number One Killer In The United States. It Is Time To Look Beyond Framingham Risk Score For Alternative 21st Century Risk Scoring System!” presented at the American Society of Hypertension 2012 Annual Scientific Meeting, New York, NY, May 20th, 2012.
  43. M. El Shahawy, M.D. et al.: “Pre-Hypertension Is a Prevalent, Unrecognized and Untreated Risk Factor for Cardiovascular Disease (CVD). Time for Paradigm Shift!” presented at the American Society of Hypertension 2012 Annual Scientific Meeting, New York, NY, May 21st, 2012.
  44. M. El Shahawy, M.D. et al.: “Beware of the Presence of Coronary Artery Calcification on any Imaging Procedure!”, presented at 7th Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography, July 20, 2012, Baltimore, Maryland
  45. M. El Shahawy, MD, MS, FESC, FACC, FAHA, FSCC, FSCCT, FASH:  “Abnormal blood pressure rise post mild exercise protocol in newly diagnosed hypertensive subjects is associated with significant cardiovascular functional/structural abnormalities” presented at the European Society of Cardiology Annual Scientific Meeting, August 28th, 2012, Munich, Germany.
  46. M. El Shahawy, M.D. et al.: “Pre-Hypertension is a Disease Associated with Significant Structural and Functional Cardiovascular Abnormalities. It is Time to Lower the Bar.", presented at the American Heart Association High Blood Pressure Research 2012 Scientific Sessions, Washington, DC, September 22, 2012.
  47. M. El Shahawy, M.D. et al.: "Perivascular Adipose Tissue and/or Epicardial Adiposity in Asymptomatic Obese Subjects is More Than a Scaffold: It is a Risk Marker for Cerebrovascular and Coronary Artery Disease"- presented at the AHA Epidemiology and Prevention/Nutrition, Physical Activity and Metabolism 2013 Scientific Sessions, March 19-22, 2013, New Orleans, LA.
  48. M. El Shahawy, M.D. et al.: "Abnormal Blood Pressure Rise post Mild Exercise in a Smoker is a Clue for Early Major Cardiovascular Structural and Functional Abnormalities" - presented at the American Society of Hypertension 28th Annual Scientific Meeting, San Francisco, California, May 16, 2013.
  49. M. El Shahawy, M.D. et al.: "Smoking is a Major Risk Factor for Structural and Functional Cerebrovascular and Cardiovascular Abnormalities"- presented at the American Society of Hypertension 28th Annual Scientific Meeting, San Francisco, California, May 17, 2013.
  50. M. El Shahawy, M.D. et al.: “Epicardial Adiposity is a Gender-Based Risk Marker for Cerebrovascular and Coronary Artery Disease in Asymptomatic Obese Subjects” – presented at the American Society of Cardiovascular Computed Tomography 8th Annual Scientific Meeting, Montreal, Canada, July 13, 2013.
  51. M. El Shahawy, M.D. et al.: “Pre-diabetes is a disease associated with significant cerebra and cardiovascular structural and functional abnormalities” – presented at the European Society of Cardiology Annual Scientific Meeting, Amsterdam, Netherlands, Europe, September 2, 2013 .
  52. M. El Shahawy, M.D. et al.: “Calcium Score vs. CRP and Pro-BNP for Early Cardiovascular Disease Risk Stratification- Which test to choose?” – to be presented at the SCCT Hawaii Scientific Meeting, Waikoloa, The Island of Hawaii, January 16, 2014.
  53. M. El Shahawy, M.D. et al.: “Abnormal blood pressure rise post mild exercise and abnormal B-type natriuretic peptide (BNP) or NT pro-BNP are markers for early cardiovascular disease risk stratification in asymptomatic subjects” – to be presented at the ESC Euro Prevent 2014 Scientific Sessions, Amsterdam, Netherlands, Europe, May 8-10, 2014.
  54. M. El Shahawy, M.D. et al.: “B-type natriuretic peptide (BNP) as a novel bio-marker for left ventricular hypertrophy in asymptomatic, uncontrolled hypertensive subjects” – to be presented ath the ESC Euro Prevent 2014 Scientific Sessions, Amsterdam, Netherlands, Europe, May 8-10, 2014.
  55. M. El Shahawy, M.D. et al.: “Is Low HDL A Risk Factor For Cardiovascular Disease?” – to be presented at the World Congress of Cardiology Scientific Sessions 2014, Melbourne, Australia, May 6, 2014.
  56. M. El Shahawy, M.D. et al.: “Smoking Even Without Comorbidities Is A Major Risk Factor For Early Cardiovascular Structural And Functional Abnormalities” – to be presented at the World Congress of Cardiology Scientific Sessions, Melbourne, Australia, May 7, 2014.
  57. M. El Shahawy, M.D. et al.: “BNP as a Marker for Left Ventricular Hypertrophy in Asymptomatic, Normotensive Individuals” – submitted for presentation at the ACC Annual Scientific meeting, Chicago, Illinois, March 2014.
  58. M. El Shahawy, M.D. et al.: “Abnormal BNP in Asymptomatic Well Controlled Hypertensive Subjects is a Novel Marker Associated with Early Cardiovascular Structural Abnormalities, i.e. Left Ventricular Hypertrophy” – submitted for presentation at the annual meeting of the American Society of Hypertension (ASH), New York, NY, May 2014.

 For a complete, up to date list please see my Curriculum Vitae